卡铂与健择联合化疗方案治疗晚期非小细胞肺癌的临床观察

目的:观察卡铂与健择联合化疗方案治疗晚期非小细胞肺癌(NSCLC)患者的临床疗效及不良反应。方法:对27例晚期NSCLC患者采用卡铂加健择联合化疗方案进行化疗,按WHO疗效及毒副反应评价标准,完成2个周期以上治疗的患者进行临床疗效及不良反应评估。结果:有效率40.7%(11/27),中位缓解期为6.5个月,中位生存期8.6个月,1a生存率37%(10/27)。主要毒副反应为骨髓抑制和消化道反应,均能耐受。结论:CBP与GEM联合化疗方案治疗晚期NSCLC患者的临床疗效较好,不良反应较轻,患者的耐受性好。

Clinical Effective Observation of Gemcitabine Combined with Carboplatin in Treating the Patients with Advanced Non-small Cell Lung Cancer

Objective To observe the clinical effect and adverse effect of gemcitabine combined with carboplatinin treating The patients with advanced non-small cell lung cancer.Methods 27 in-patients,aged from 48 to 75 with advanced non-smal cell lung cancer(ⅢA~Ⅳ)were treated with combined regimen of gemcitabine plus carboplatin,the clinical effect and adverse effect were evaluated after two cycles of chemotherapy according to WHO standard.Results The effective rate was 40.7%(11/27);the median resmssion time was 6.5 months and median survival time was 8.6 months and one-year survival rate was 37%(10/27);the main toxicity included the tolerable alimentary tract reaction and bone marrow depression.Conclusion The combination regimen of gemcitabine plus carboplatinin treating the patients with intermediate-or late-stage non-small cell lung cancer is effective and with light tolerated adverse effect.